高水平的血清Mac-2结合蛋白糖基化异构体（M2BPGi）预测用核苷

StephenW

J Gastroenterol. 2017 Dec 29. doi: 10.1007/s00535-017-1424-0. [Epub ahead of print]
High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.Shinkai N1, Nojima M2, Iio E3, Matsunami K3, Toyoda H4, Murakami S1, Inoue T5, Ogawa S1, Kumada T4, Tanaka Y6.
Author information
1Departments of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.2Center for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan.3Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.4Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.5Department of Clinical Laboratory, Nagoya City University Hospital, Nagoya, Japan.6Departments of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. [email protected].

AbstractBACKGROUND: Nucleot(s)ide analogues (NA) can reduce the risk of hepatocellular carcinoma (HCC), but not completely prevent its development.
METHODS: Two hundred and thirty-four chronic hepatitis B patients virologically well controlled with entecavir or tenofovir disoproxil fumarate for more than 1 year were enrolled in this study. Over the median observation period of 51 (12-142) months, 24 of 234 patients developed HCC. We quantified HBV markers, alpha-fetoprotein (AFP) and Mac-2-binding protein glycosylation isomer (M2BPGi) at baseline and 48 weeks after therapy.
RESULTS: Serum AFP and M2BPGi tended to decline from baseline to 48 weeks after treatment both in patients who did and those who did not develop HCC. Univariate Cox regression analysis indicated that serum M2BPGi levels ≥ 1.215 COI at 48 weeks were associated with HCC development [hazard ratio (HR) 5.73; p ≤ 0.001]. Multivariate analysis showed that male sex (HR 5.6; p = 0.01), AFP ≥ 9.65 ng/ml (HR 22.01; p ≤ 0.001), M2BPGi ≥ 1.215 (HR 5.07; p = 0.004) at 48 weeks were significant independent predictive factors for HCC development. Based on a scoring system consisting of three factors above described, Kaplan-Meier analysis for four groups (score 0, 1, 2, ≥ 3), revealed significant differences in cumulative HCC occurrence for each group within 2 years. The rate of incidence of HCC was 0, 5.4, 23.4, and 75% in each group, respectively.
CONCLUSIONS: In patients receiving NA therapy, higher M2BPGi at 48 weeks, as well as male sex and higher AFP at 48 weeks were independent risk factors for HCC development.


KEYWORDS: Alpha-fetoprotein; Hepatocellular carcinoma; Mac-2-binding protein glycosylation isomer; Nucleot(s)ide analogue

PMID:29288305DOI:10.1007/s00535-017-1424-0

StephenW

J Gastroenterol。 2017年12月29日doi：10.1007 / s00535-017-1424-0。 [电子版提前打印]
高水平的血清Mac-2结合蛋白糖基化异构体（M2BPGi）预测用核苷酸类似物治疗的乙型肝炎患者中肝细胞癌的发展。
Shinkai N1，野岛M2，Iio E3，松浪K3，丰田H4，村上S1，井上T5，小川S1，熊田T4，田中Y6。
作者信息

1
    日本名古屋市名古屋市立大学医学研究科病毒与肝脏科。
2
    东京大学医学研究所转化研究中心，日本东京。
3
    日本名古屋市名古屋市立大学医学研究科胃肠病学与代谢学系。
4
    日本大垣市大垣市立医院消化内科。
五
    日本名古屋市名古屋市大学医院临床实验室。
6
    日本名古屋市名古屋市立大学医学研究科病毒与肝脏科。 [email protected]。

抽象
背景：

核酸类似物（NA）可降低肝细胞癌（HCC）的风险，但不能完全阻止其发展。
方法：

234例慢性乙型肝炎患者使用恩替卡韦或替诺福韦酯替诺福韦延长1年以上，在51（12-142）个月的中值观察期间，234例患者中有24例发生HCC。我们在基线和治疗后48周量化了HBV标记，甲胎蛋白（AFP）和Mac-2结合蛋白糖基化异构体（M2BPGi）。
结果：

治疗后48周，血清AFP和M2BPGi均趋于下降，无论是那些还是不发展HCC的患者。单变量Cox回归分析显示，48周时血清M2BPGi水平≥1.215COI与HCC发展相关[危险比（HR）5.73; p≤0.001]。多因素分析显示，48周时男性（HR 5.6; P = 0.01），AFP≥9.65 ng / ml（HR 22.01; p≤0.001），M2BPGi≥1.215（HR 5.07; p = 0.004） HCC发展。基于由上述三个因素组成的评分系统，四组（分数0,1,2，≥3）的Kaplan-Meier分析揭示了在两年内每个组的累积HCC发生率的显着差异。肝癌发病率分别为0,5.4,23.4和75％。
结论：

在接受NA治疗的患者中，48周时较高的M2BPGi以及48周时的男性和较高的AFP是HCC发展的独立危险因素。
关键词：

甲胎蛋白;肝细胞癌; Mac-2结合蛋白糖基化异构体; Nucleot（s）ide类似物

结论：
    29288305
DOI：
    10.1007 / s00535-017-1424-0